|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012显示文摘 | R. Phillip Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell | 2013 | Critical Care Medicine2013，，2： | 12 |
| 2 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012显示文摘 | R. P. Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell Derek | 2013 | Intensive Care Medicine2013，，2： | 7 |
| 3 | Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis显示文摘 | Raghuwansh P. Sah Suresh T. Chari Rahul Pannala Aravind Sugumar Jonathan E. Clain Michael J. Levy Randall K. Pearson Thomas C. Smyrk Bret T. Petersen Mark D. Topazian Naoki Takahashi Michael B. Farnell Santhi S. Vege | 2010 | Gastroenterology2010，，1： | 3 |
| 4 | Histologic and Imaging Features of Mural Nodules in Mucinous Pancreatic Cysts显示文摘 | Ning Zhong Lizhi Zhang Naoki Takahashi Vladislav Shalmiyev Marcia Irene Canto Jonathan E. Clain John C. Deutsch John DeWitt Mohamad A. Eloubeidi Ferga C. Gleeson Michael J. Levy Shawn Mallery Massimo Raimondo Elizabeth Rajan Tyler Stevens Mark Topazian | 2012 | Clinical Gastroenterology and Hepatology2012，，2： | 2 |
| 5 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 6 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines显示文摘 | Clyde W. Yancy Mariell Jessup Biykem Bozkurt Javed Butler Donald E. Casey Mark H. Drazner Gregg C. Fonarow Stephen A. Geraci Tamara Horwich James L. Januzzi Maryl R. Johnson Edward K. Kasper Wayne C. Levy Frederick A. Masoudi Patrick E. McBride John J.V. | 2013 | Circulation2013，，16： | 2 |
| 7 | FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation显示文摘Tyrosine kinase inhibitors(TKIs)targeting FLT3 have shown activity but when used alone have achieved limited success in clinical trials,suggesting the need for combination with other drugs.We investigated the combination of FLT3 TKIs(Gilteritinib or Sorafenib),with Venetodax,a BCL-2 selective inhibitor(BCL-2i),on FLT3/ITD leukemia cells.The combination of a FLT3 TKI and a BCL-2i synergistically reduced cell proliferation and enhanced apoptosis/cell death in FLT3/ITD cell lines and primary AML samples.Venetoclax also re-sensitized FLT3 TKI-resistant cells to Gilteritinib or Sorafenib treatment,mediated through MAPK pathway inhibition.Gilteritinib treatment alone dissociated BIM from MCL-1 but increased the binding of BIM to BCL-2.Venetoclax treatment enhanced the binding of BIM to MCL-1 but dissociated BIM from BCL-2.Treatment with the drugs together resulted in dissociation of BIM from both BCL-2 and MCL-1,with an increased binding of BIM to the cell death mediator BAX,leading to increased apoptosis.These findings suggest that Venetoclax mitigates the unintended pro-survival effects of FLT3 TKI mainly through the dissociation of BIM and BCL-2 and also decreased BIM expression.This study provides evidence that the addition of BCL-2i enhances the effect of FLT3 TKI therapy in FLT3/ITD AML treatment. | Ruiqi Zhu Li Li Bao Nguyen Jaesung Seo Min Wu Tessa Seale Mark Levis Amy Duffield Yu Hu Donald Small | 2021 | Signal Transduction and Targeted Therapy2021，6，6： | 2 |
| 8 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 9 | Percutaneous transluminal angioplasty balloons for endoscopic ultrasound-guided pancreatic duct interventions显示文摘BACKGROUND Endoscopic ultrasound(EUS)-guided main pancreatic duct(PD)access may be used when conventional endoscopic retrograde cholangiopancreatography(ERCP)techniques fail.The use of a percutaneous transluminal angioplasty balloon(PTAB),originally developed for vascular interventions,can be used to facilitate transmural(e.g.,transgastric)PD access and to dilate high-grade pancreatic strictures.AIM To describe the technique,efficacy,and safety of PTABs for EUS-guided PD interventions.METHODS Patients who underwent EUS with use of a PTAB from March 2011 to August 2021 were retrospectively identified from a tertiary care medical center supply database.PTABs included 3-4 French angioplasty catheters with 3-4 mm balloons designed to use over a 0.018-inch guidewire.The primary outcome was technical success.Secondary outcomes included incidence of adverse events(AEs)and need for early reintervention.RESULTS A total of 23 patients were identified(48%female,mean age 55.8 years).Chronic pancreatitis was the underlying etiology in 13(56.5%)patients,surgically altered anatomy(SAA)with stricture in 7(30.4%),and SAA with post-operative leak in 3(13.0%).Technical success was achieved in 20(87%)cases.Overall AE rate was 26%(n=6).All AEs were mild and included 1 pancreatic duct leak,2 cases of post-procedure pancreatitis,and 3 admissions for post-procedural pain.No patients required early re-intervention.CONCLUSION EUS-guided use of PTABs for PD access and/or stricture management is feasible with an acceptable safety profile and can be considered in patients when conventional ERCP cannulation fails. | Jad P AbiMansour Barham K Abu Dayyeh Michael J Levy Andrew C Storm John A Martin Bret T Petersen Ryan J Law Mark D Topazian Vinay Chandrasekhara | 2022 | World Journal of Gastrointestinal Endoscopy2022，14，8： | 2 |
| 10 | End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients显示文摘AIM To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangio-pancreatography (ERCP) adverse events (AEs). METHODS We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9^(th) Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.RESULTS There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95% CI: 1.4-2.1, ~aP < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, ~aP < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, ~aP < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95% CI: 5.0-6.7 d, ~aP < 0.001) and higher hospitalization charges aMD = $+82064 (95%CI: $68221-$95906, ~aP < 0.001). CONCLUSION ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes. | Tarek Sawas Fateh Bazerbachi Samir Haffar Won K Cho Michael J Levy John A Martin Bret T Petersen Mark D Topazian Vinay Chandrasekhara Barham K Abu Dayyeh | 2018 | World Journal of Gastroenterology2018，24，41： | 2 |
| 11 | Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer显示文摘 | Val J. Lowe Fargol Booya J. G. Fletcher Mark Nathan Eric Jensen Brian Mullan Eric Rohren Maurits J. Wiersema Enrique Vazquez-Sequeiros Joseph A. Murray Mark S. Allen Michael J. Levy Jonathan E. Clain | 2005 | Molecular Imaging and Biology2005，，6： | 2 |
| 12 | EUS-guided biliary drainage for patients with malignant biliary obstruction with an indwelling duodenal stent (with videos)显示文摘 | Mouen A. Khashab Larissa L. Fujii Todd H. Baron Marcia Irene Canto Christopher J. Gostout Bret T. Petersen Patrick I. Okolo Mark D. Topazian Michael J. Levy | 2012 | Gastrointestinal Endoscopy2012，，1： | 2 |
| 13 | Disconnected pancreatic duct syndrome in severe acute pancreatitis: clinical and imaging characteristics and outcomes in a cohort of 31 cases显示文摘 | Mario Pelaez-Luna Santhi Swaroop Vege Bret T. Petersen Suresh T. Chari Jonathan E. Clain Michael J. Levy Randal K. Pearson Mark D. Topazian Michael B. Farnell Michael L. Kendrick Todd H. Baron | 2008 | Gastrointestinal Endoscopy2008，，1： | 2 |
| 14 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012显示文摘 | R. P. Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell Derek | 2013 | Intensive Care Medicine2013，，2： | 2 |
| 15 | Arterial Spin Labeling Identifies Tissue Salvage and Good Clinical Recovery After Acute Ischemic Stroke显示文摘 | Andrew Bivard Peter Stanwell Christopher Levi Mark Parsons | 2013 | Journal of Neuroimaging2013，，3： | 2 |
| 16 | Diagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience显示文摘 | Suresh T. Chari Thomas C. Smyrk Michael J. Levy Mark D. Topazian Naoki Takahashi Lizhi Zhang Jonathan E. Clain Randall K. Pearson Bret T. Petersen Santhi Swaroop Vege Michael B. Farnell | 2006 | Clinical Gastroenterology and Hepatology2006，，8： | 1 |
| 17 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012显示文摘 | R. Phillip Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell | 2013 | Critical Care Medicine2013，，2： | 1 |
| 18 | Acute Heart Failure Syndromes: Emergency Department Presentation, Treatment, and Disposition: Current Approaches and Future Aims: A Scientific Statement From the American Heart Association显示文摘 | Neal L. Weintraub Sean P. Collins Peter S. Pang Phillip D. Levy Allen S. Anderson Cynthia Arslanian-Engoren W. Brian Gibler James K. McCord Mark B. Parshall Gary S. Francis Mihai Gheorghiade | 2010 | Circulation2010，，： | 1 |
| 19 | EUS-guided trucut biopsy in establishing autoimmune pancreatitis as the cause of obstructive jaundice显示文摘 | Michael J. Levy Raghuram P. Reddy Maurits J. Wiersema Thomas C. Smyrk Jonathan E. Clain Gavin C. Harewood Randall K. Pearson Elizabeth Rajan Mark D. Topazian Tony E. Yusuf Suresh T. Chari Bret T. Petersen | 2005 | Gastrointestinal Endoscopy2005，，3： | 1 |
| 20 | Discrimination of Benign and Neoplastic Mucosa with a High-Resolution Microendoscope (HRME) in Head and Neck Cancer显示文摘 | Peter Vila Chan Park Mark Pierce Gregg Goldstein Lauren Levy Vivek Gurudutt Alexandros Polydorides James Godbold Marita Teng Eric Genden Brett Miles Sharmila Anandasabapathy Ann Gillenwater Rebecca Richards-Kortum Andrew Sikora | 2012 | Annals of Surgical Oncology2012，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员